AYTU BIOPHARMA INC

For the period ended Dec 31, 2023. Filed Feb 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2023 · Filed Feb 14, 2024

AYTU$1.81+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Additional · Total
Common Stock · Paid-in · Accumulated · Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balances, June 30, 2023	5,517,174	$1	$343,485	$(304,129)	$39,357
Stock-based compensation expense	13,061	—	930	—	930
Net loss	—	—	—	(8,120)	(8,120)
Balances, September 30, 2023	5,530,235	$1	$344,415	$(312,249)	$32,167
Stock-based compensation expense	108	—	820	—	820
Issuance of common stock with exercise of warrants	37,004	—	86	—	86
Net loss	—	—	—	(220)	(220)
Balances, December 31, 2023	5,567,347	$1	$345,321	$(312,469)	$32,853

Additional · Total
Common Stock · Paid-in · Accumulated · Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balances, June 30, 2022	1,928,941	$—	$331,386	$(287,078)	$44,308
Stock-based compensation expense	(1,666)	—	1,177	—	1,177
Issuance of common stock, net of issuance cost	1,194,196	—	3,564	—	3,564
Net loss	—	—	—	(701)	(701)
Balances, September 30, 2022	3,121,471	$—	$336,127	$(287,779)	$48,348
Stock-based compensation expense	(19,228)	—	3,067	—	3,067
Issuance of common stock, net of issuance cost	280,902	—	1,095	—	1,095
Net loss	—	—	—	(6,693)	(6,693)
Balances, December 31, 2022	3,383,145	$—	$340,289	$(294,472)	$45,817

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.